ello, everyone, and how are you are doing? STAT reporter Rebecca Robbins here, and I’m doing fine this morning, thanks to a steaming cup of stimulation. (No special flavor, though, I’m sorry to report.) Let’s get started on what you came here for: headlines from the world of pharma. And do send us a note if you spot anything interesting …

Novo Nordisk (NVO) scored a victory with its type 2 diabetes drug semaglutide in a late-stage trial, Reuters informs us. The drug combined with metformin successfully reduced glucose levels when tested head-to-head against a competitor from Eli Lilly (LLY).

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy